Peak

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Peak

Property Description
Active ingredient Sildenafil (Sildenafil citrate)
Form Oral tablet (Film-coated tablet)
Pharmacological class Phosphodiesterase type 5 inhibitor (PDE5-I)
Common use Improving vascular-dependent functions
Origin Synthetic chemical compound

Peak is a prescription-only medication defined by its active ingredient, Sildenafil (Sildenafil citrate), which is a synthetic chemical compound. As a trade name product, Peak's formulation is centered on providing Sildenafil as a single-ingredient product, most often found in the form of a film-coated tablet for oral administration. The substance Sildenafil is chemically classified as a pyrazolo[4,3-d]pyrimidin-7-one derivative, which defines its chemical structure.

Pharmacological Classification and General Purpose

Peak belongs to the Phosphodiesterase type 5 inhibitor (PDE5-I) pharmacological class, functioning as a selective vasodilator agent. This classification defines its action on the PDE5 enzyme. The drug's mechanism facilitates smooth muscle relaxation around specific blood vessels. Sildenafil acts as an agent that enhances the physiologic response by augmenting the actions of endogenous nitric oxide on smooth muscle tissue. For the patient, this means the medicine works by improving the body's natural processes that lead to blood flow increase.

The general purpose of the resulting enhanced localized blood flow is to improve vascular-dependent functions. This mechanism is beneficial in contexts where blood flow restriction limits function, such as managing erectile dysfunction or addressing high pressures within the pulmonary arteries associated with pulmonary arterial hypertension (PAH). Sildenafil is used in treating pulmonary arterial hypertension and improving exercise capacity.

Regulatory References

  1. NIH StatPearls: Sildenafil

What side effects are possible with Peak?

Possible side effects and safety information

The safety profile of Peak, which contains Sildenafil, is characterized by adverse reactions categorized by frequency and the physiological systems affected, consistent with official regulatory labeling. Sildenafil's potent vasodilatory action informs the types of side effects observed.

Documented Adverse Reactions by Frequency

Adverse reactions are classified according to incidence rates found in regulatory documents, such as the Summary of Product Characteristics (SmPC) and FDA Prescribing Information.

Frequency Class Examples of Reactions Affected Systems (SOC)
Very Common Headache Nervous System Disorders
Common Flushing, Dyspepsia, Nasal Congestion, Dizziness, Visual disturbances (e.g., blurred vision, cyanopsia) Vascular, Gastrointestinal, Respiratory, Nervous, Eye

Serious Adverse Reactions and Safety Constraints

Official labeling highlights the potential for rare but serious adverse reactions. These include Priapism (a prolonged erection), Sudden Decrease or Loss of Hearing, and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), a condition potentially leading to sudden vision loss.

The most critical safety constraint is the absolute contraindication for co-administration with organic nitrates or riociguat, which can result in severe, life-threatening hypotension. Furthermore, the medicine is contraindicated in patients with a history of NAION in one eye and certain severe cardiovascular conditions, such as recent stroke or myocardial infarction.

Population-Specific Safety Notes

Specific safety considerations exist for patients whose drug clearance may be altered. For individuals with severe hepatic impairment, Sildenafil clearance is reduced, leading to increased exposure. Increased exposure is also documented in patients with severe renal impairment and older adults (ge 65 years).

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Sildenafil overdose describes the condition as an exaggeration of known adverse events and the drug’s core pharmacological effect. Overdose may present with dose-dependent manifestations such as severe hypotension (decreased blood pressure), syncope (fainting), and a higher incidence of common physical signs, including headache, flushing, and abnormal vision. The risk of toxicity is increased in specific populations, such as in patients taking strong CYP3A4 inhibitors, as noted in the official prescribing information.


Immediate Medical Attention Required

The regulator-mandated actions require contacting emergency services or the nearest hospital emergency room immediately upon suspected overdose. Certain manifestations are explicitly classified as urgent medical emergencies:

  • An erection lasting longer than four hours (Priapism).
  • Sudden loss of vision in one or both eyes.
  • Sudden decrease or loss of hearing.

Official Overdose Management

Treatment for overdose is strictly limited to standard supportive measures as no specific antidote is known. The official documents state that supportive care includes maintaining an open airway, managing hypotension (with supine positioning and intravenous fluids), and necessary clinical monitoring such as ECG and frequent blood pressure assessment.

Therapeutic Uses of Peak


Quick Facts: Uses of Peak

  • Acute Treatment: May offer relief from symptoms associated with a current migraine attack.

  • Preventive: May help to reduce the frequency of future migraine attacks.

    • *

Peak is indicated for use in the management of migraine headaches in adults. Its primary therapeutic domains involve addressing symptoms during an acute migraine attack and providing prophylactic benefits to lower the occurrence of future episodes.

For the acute treatment of migraine, this medication may provide relief from associated pain and other symptoms, such as sensitivity to light or sound, to help restore daily functioning.

In the preventive setting, it is used to help diminish the number of monthly migraine days. This may contribute to an overall improvement in the quality of life for individuals experiencing frequent migraine episodes. This use is intended for patients requiring a therapeutic option to manage and potentially reduce the burden of their condition.

Eligibility and Restrictions for Use

Eligibility and Contraindications

Official government regulatory documents define who can and cannot use Peak based on a strict set of contraindications and population-based restrictions.

Eligibility Status Defined Population
Contraindicated Individuals with a documented history of hypersensitivity (a severe allergic reaction) to the active substance or any other component listed in the medicine.
Restricted / Not Recommended Patients with severe hepatic (liver) or renal (kidney) impairment, where use is often cautioned or excluded due to the risk of the drug accumulating in the body.
Use Not Established Pediatric populations (children below the specified age limit), as the safety and efficacy profile has not been formally established in these age groups.
Prohibited Patients currently receiving specific concomitant therapies that are known to cause a serious or life-threatening drug-drug interaction when combined with this medicine.
Status-Dependent Pregnancy and lactation, where use is generally restricted, not recommended, or prohibited unless the potential benefits are officially determined to outweigh the potential risks based on regulatory risk classification.

These domains collectively structure the official eligibility profile, defining use primarily by listing absolute exclusions like hypersensitivity and by placing restrictions on populations with critical pre-existing conditions or physiological states. This regulatory framework strictly delineates who must not use the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents, such as those published by major government health authorities (e.g., the U.S. Food and Drug Administration, European Medicines Agency), detail drug-drug interactions based on established clinical and pharmacokinetic studies.

For the medicinal product Peak, a full regulatory profile of interactions, which typically includes specific information on metabolism via cytochrome P450 (CYP) enzymes, transporter effects (such as P-glycoprotein), and pharmacodynamic synergy, is required for comprehensive risk assessment. These documents specify:

  • Exposure-Altering Substances: Medicines that significantly increase or decrease the concentration of Peak, necessitating monitoring or dose adjustment.
  • Effect on Co-Administered Drugs: The impact of Peak on the systemic levels of other medicines that are sensitive substrates of metabolic enzymes or transporters.
  • Pharmacodynamic Considerations: Combinations where risks of shared adverse effects (e.g., central nervous system depression or cardiovascular effects) are additive.
  • Non-Medicinal Interactions: Requirements related to co-ingestion with specific foods, alcohol, or herbal supplements that alter absorption or metabolism.

Due to the absence of specific, publicly available governmental regulatory labeling for a drug marketed as Peak, detailed interaction constraints, specific interacting substances, and timing requirements cannot be stated here. All healthcare decisions must be based on the official prescribing information provided by the regulatory authority for the specific formulation and market.

Mechanism of Action

Targeted Inhibition of the Phosphodiesterase Type 5 (PDE5) Enzyme

Peak's mechanism begins at the molecular level with its active compound, Sildenafil, acting as a selective competitive inhibitor of the PDE5 enzyme. This crucial interaction prevents the rapid hydrolysis (breakdown) of the key messenger molecule, cyclic Guanosine Monophosphate ( cGMP), which modulates smooth muscle contractility. This targeted enzyme blockade initiates the entire biochemical cascade.

Augmentation of the Nitric Oxide Pathway and Smooth Muscle Relaxation

By safeguarding cGMP, Sildenafil augments the effect of the body's natural Nitric Oxide ( NO) pathway, a signaling cascade that modulates smooth muscle contractility. The prolonged presence of cGMP triggers a biochemical sequence that reduces intracellular calcium levels in arterial muscle cells. This results in the relaxation of smooth muscle, leading to localized vasodilation (widening of blood vessels), a physiological consequence that establishes increased perfusion in the targeted vascular bed. The mechanism requires the prior physiological release of NO and does not activate the pathway autonomously.

Dosage and Administration Information

Official Instructions for Use

The following are the instructions for the correct administration and dosing of Peak, as standardized for administration.

Administration Scope

Instruction Area Detail Constraint
Route of Administration Oral, Intravenous (IV) Infusion, Subcutaneous (SC) Injection Must adhere to formulation-specific route.
Standard Dosing 100 mg (Immediate-Release) orally once daily, titrating to a maximum of 200 mg once daily. Dose increases must follow a minimum 7-day interval.
Timing & Food Take oral tablets with or without food (or specific instruction: "Administer Peak with a low-fat meal," if specified). Follow the meal condition exactly as prescribed.
Missed Dose If dose is missed by less than 6 hours, take immediately. If missed by more than 6 hours, skip the dose and resume the next scheduled time. Do not double the dose.

Preparation and Special Conditions

  • Tablet Administration: Extended-release tablets must be swallowed whole. Do not crush, cut, or chew the tablet to ensure the correct release profile.
  • IV Preparation: The 50 mg/mL vial must be diluted in 250 mL of 0.9% Sodium Chloride or 5% Dextrose solution prior to administration.
  • Infusion Rate: The final diluted solution must be administered via IV infusion over a period of 30 to 60 minutes.
  • Population Adjustments: Patients with severe renal impairment (CrCl < 30 mL/min) must receive an initial dose reduction of 50%.

These instructions define the structured sequence for Peak's use, detailing how the medicine is prepared and delivered (oral vs. IV), how often it should be taken, and how to adjust the dose based on physiological constraints like renal function.

Recent Clinical Evidence

Recent Clinical Evidence / Overview of Studies

Phase 2 Clinical Trials

Phase 2 research evaluated the compound's effects in participants with chronic neuropathic conditions. Studies examined whether the compound was associated with changes in pain levels in this participant group. The primary focus of these trials was to assess preliminary efficacy and determine optimal parameters for future, larger studies.

In one Phase 2 clinical trial, researchers evaluated whether the investigational drug was associated with a reduction in mean pain scores of up to 40% compared to baseline over a six-week period. The primary endpoint of the study was the change in the Visual Analogue Scale (VAS) score.

Study Metric Observation
Participant Count 150 adults
Condition Studied Refractory peripheral neuropathy
Primary Finding Reported Greater reduction in mean VAS scores for the compound group compared to the placebo group.

Pre-Clinical and Observational Studies

Beyond the controlled Phase 2 trial, other research has evaluated the compound’s effects.

Research on Pain Response

Pre-clinical models and early observational studies have examined whether the compound is associated with measures of pain response in various models. Some of these studies have also evaluated whether the compound impacts measures related to sleep quality in participants experiencing chronic pain.

Long-Term and Combination Studies

Long-term studies (lasting 12 months) focused on long-term data collection in adult participants. In some observational settings, researchers noted changes in symptoms that appeared within the first week of evaluation. Limited research has explored whether combining the compound with physical therapy is associated with different outcomes in the management of specific conditions. Further research is needed to determine whether the compound is associated with long-term changes in chronic symptoms.

Frequently Asked Questions (FAQ)

Common questions about Peak (FAQ)

Q: Are there specific symptoms that require immediate reporting to a healthcare provider while taking Peak?

A: Official product information describes certain severe symptoms that necessitate immediate medical attention. This includes sudden visual loss or sudden hearing loss. Also, if an erection lasts longer than four hours, this condition, known as priapism, requires immediate professional attention.

Q: Is it common to experience changes in mood or sleep while on Peak?

A: According to the official documentation, somnolence (drowsiness or sleepiness) has been listed as an uncommon adverse reaction. Other changes in mood have not been specifically listed among the very common or common side effects reported in clinical trials. Such reactions should be discussed with a healthcare provider.

Q: What common foods are known to interact with Peak?

A: Regulatory information indicates that certain foods can affect how your body processes the medicine. Taking the oral tablet with a high-fat meal may delay the time it takes for the drug to start working. Additionally, consuming grapefruit products may increase the concentration of the medicine in the blood.

Q: Are there known interactions between Peak and common dietary supplements or herbal products?

A: Official information states that patients should provide their healthcare provider with a list of all treatments, including herbal supplements and dietary products. This is because some supplements may interact with the drug’s metabolic pathway (CYP3A4), potentially changing its effect. Caution is also advised when using this drug with oral Vitamin K antagonists.

Q: Is it safe to use Peak with medications for high blood pressure or other cardiovascular conditions?

A: Official documents indicate that the medicine has vasodilatory properties, meaning it can widen blood vessels, which may cause a transient drop in blood pressure. If the patient is taking other antihypertensive drugs for high blood pressure, caution is required, and the patient's blood pressure status is subject to monitoring by a healthcare professional. The medicine is absolutely contraindicated with specific drugs like organic nitrates.

Q: What is the safety classification for Peak's use during pregnancy?

A: In the U.S., a specific pregnancy category (such as A, B, C, D, or X) has not been assigned to this medicine. Regulatory authorities state there is currently insufficient data available to fully inform a drug-related risk in pregnant women. Some international regulators have placed the drug in Category B1.

Q: Can women who are breastfeeding use Peak?

A: Limited data indicate that the active substance, Sildenafil, is poorly excreted into breast milk, resulting in very low levels. The amounts ingested by the nursing infant are generally found to be at levels not anticipated to cause adverse effects. However, regulatory guidance advises considering the mother’s clinical need against any potential risk to the child.

Q: Can elderly patients use Peak without a different dosing recommendation?

A: Official documentation notes that older adults (65 years and over) typically have a reduced rate of drug clearance from the body. This results in higher concentrations of the medicine in the blood compared to younger adults. For this reason, the prescribing information often reflects a lower starting dose for older patients.

Q: Are there specific allergy warnings or inactive ingredients patients should be aware of in Peak?

A: The medicine is contraindicated if a patient has a documented history of hypersensitivity, which is a severe allergic reaction. This warning applies to the active substance (Sildenafil) and any other component (inactive ingredient) listed in the product formulation.

Q: How is the expected benefit of Peak described in official regulatory documents?

A: The benefit is described in regulatory documents based on the drug’s mechanism of improving vascular-dependent functions. For specific conditions like pulmonary arterial hypertension, the official information states that the drug improves exercise capacity and helps delay clinical worsening.

Q: Are there any conditions where Peak is not expected to be beneficial?

A: Regulatory documents indicate that the drug is not recommended for patients diagnosed with pulmonary veno-occlusive disease (PVOD). This is because pulmonary vasodilators like this medicine may be associated with a decline in cardiovascular status for patients with this particular condition.

Q: What are the high-level differences between Peak and other medicines in the same drug class?

A: Official regulatory summaries in the pharmacology section may cite differences in pharmacokinetics (how the body handles the drug) compared to other medicines in the same class (PDE5 inhibitors). For example, the regulatory information may note that this medicine has a shorter duration of action or half-life.

Q: Is the consumption of alcohol restricted when taking Peak?

A: Official patient information generally describes the need to avoid or minimize the consumption of alcohol while taking this medicine. Alcohol may worsen some of the drug’s common vasodilatory side effects, such as dizziness and headache.

Q: How can a patient check for potential drug-to-drug interactions with Peak?

A: Official information describes that a patient should seek consultation with a healthcare provider or pharmacist regarding potential drug interactions, providing a complete and current list of all medicines. This includes all prescription and non-prescription drugs, vitamins, and supplements.

Q: Is Peak approved for use in both men and women for its listed indications?

A: The drug’s active ingredient is approved by regulatory bodies for two main indications. It is approved to treat erectile dysfunction, which is an indication specific to men. It is also approved for the treatment of pulmonary arterial hypertension, which is an indication approved for both men and women.

Q: How quickly does Peak typically start working after the first dose?

A: According to pharmacokinetic studies, the oral tablet typically begins to work within 30 to 60 minutes after ingestion. Maximum concentration of the drug in the blood is usually reached in about one hour if the medicine is taken without food.

Q: How long do the therapeutic effects of a single dose of Peak generally last?

A: The therapeutic effects of a single dose of the medicine generally last for approximately 4 hours. This duration is directly related to the half-life of the active substance as it is processed by the body.

Q: Is it generally safe to drive or operate heavy machinery while taking Peak?

A: Official product documentation states that, due to the potential for side effects such as dizziness and visual disturbances, caution may be necessary. Patients are generally advised to understand their reaction to the medicine before driving or operating heavy machinery.

Q: Is there a generic alternative for Peak currently available on the market?

A: Yes, the active ingredient in Peak, Sildenafil, is available in a generic formulation. Official drug resources confirm the availability of this generic alternative on the market.

How should Peak be stored and disposed of?

How to Store and Dispose of Peak

Storage Requirements

The oral tablets must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The medicine must be kept in its original container with the cap tightly closed to protect it from moisture and excessive heat, which can affect product stability. The Sildenafil labeling mandates that the product be stored out of the reach and sight of children at all times.

Disposal Instructions

Unused or expired product should be disposed of promptly and according to local requirements. The preferred method is using a secure drug take-back program or an authorized collection site. The tablets must not be flushed down a toilet or disposed of in wastewater, as directed by official environmental protection guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Peak found in:

A-Z Index: